---
document_datetime: 2025-12-02 05:39:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/opdualag.html
document_name: opdualag.html
version: success
processing_time: 0.1107222
conversion_datetime: 2025-12-25 13:25:14.494979
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Opdualag

[RSS](/en/individual-human-medicine.xml/67604)

##### Authorised

This medicine is authorised for use in the European Union

relatlimab / nivolumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Opdualag](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78234)
- [More information on Opdualag](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Opdualag is a medicine used as a first-line treatment for melanoma (a type of skin cancer) that has spread or cannot be surgically removed. It is used for patients from 12 years of age whose cancer cells produce a low level (&lt;1%) of a protein called PD-L1.

Opdualag contains the active substances nivolumab and relatlimab.

Expand section

Collapse section

## How is Opdualag used?

Before starting treatment with Opdualag, the patient should have a test to show that their cancer cells produce low levels of PD-L1 (&lt;1%).

The medicine is given as an infusion into a vein over 30 minutes once every 4 weeks. Treatment should continue for as long as the patient benefits from it or does not have intolerable side effects. If certain side effects occur, the doctor may delay doses or stop treatment altogether.

For more information about using Opdualag, see the package leaflet or contact your doctor or pharmacist.

## How does Opdualag work?

The active substances in Opdualag, nivolumab and relatlimab, are monoclonal antibodies, proteins designed to attach to specific receptors (targets).

Nivolumab attaches to a receptor called PD-1 on cells of the immune system called T cells. Cancer cells can produce proteins (PD-L1 and PD-L2) on their surface that attach to the PD-1 receptor and switch off the activity of the T cells, preventing them from attacking the cancer. By attaching to the receptor, nivolumab prevents PD-L1 and PD-L2 from switching off the T cells, thereby increasing the ability of the immune system to kill cancer cells.

Relatlimab attaches to and blocks another receptor known as LAG?3. LAG-3 is involved in reducing the immune response By blocking LAG-3, relatlimab causes the activation of more T cells, thereby increasing the ability of the immune system to attack and kill the cancer cells.

Using nivolumab and relatlimab together is more effective at killing the cancer cells than using them alone.

## What benefits of Opdualag have been shown in studies?

A main study involving 714 patients with previously untreated advanced melanoma showed that Opdualag was effective at slowing the worsening of the disease in those patients whose cancer produced a low level amount of PD-L1.

Patients with low levels of PD-L1 (&lt;1%) who had Opdualag treatment lived for 6.7 months without their disease getting worse. This compares with 3 months for patients having treatment with nivolumab alone.

## What are the risks associated with Opdualag?

The most common side effects with Opdualag (which may affect more than 1 in 10 people) are tiredness, pain in muscles and bones, rash, joint pain, diarrhoea, itching, headache, nausea, cough reduced appetite, hypothyroidism (an underactive thyroid gland), abdominal pain, vitiligo (white patches on the skin), fever, constipation, urinary tract infection (infection of the parts of the body that collect and pass out urine), dyspnoea (difficulty breathing), and vomiting.

The most common serious side effects are adrenal insufficiency (where the adrenal glands on top of the kidneys do not make enough of certain hormones), anaemia (low levels of red blood cells), back pain, colitis (inflammation in the large bowel), diarrhoea, myocarditis (inflammation of heart muscle), pneumonia (infection of the lungs) and urinary tract infection.

For the full list of side effects and restrictions, see the package leaflet.

## Why is Opdualag authorised in the EU?

The main study showed that Opdualag was effective at slowing the worsening of the disease in those patients whose cancer produces a small amount of PD-L1 (&lt;1%). Although there are more side effects with Opdualag than with nivolumab alone, the benefits in delaying worsening of the disease outweigh the risks in these patients. The European Medicines Agency therefore recommended authorising the medicine in the EU.

## What measures are being taken to ensure the safe and effective use of Opdualag?

The company will provide a patient card with information on the risks of the medicine as well as instructions on when to contact their doctor if they have symptoms of immune-related side effects.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Opdualag have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Opdualag are continuously monitored. Suspected side effects reported with Opdualag are carefully evaluated and any necessary action taken to protect patients.

## Other information about Opdualag

Opdualag received a marketing authorisation valid throughout the EU on 15 September 2022.

Opdualag : EPAR - Medicine Overview

Reference Number: EMA/706008/2022

English (EN) (116.34 KB - PDF)

**First published:** 20/09/2022

[View](/en/documents/overview/opdualag-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-122)

български (BG) (132.27 KB - PDF)

**First published:**

20/09/2022

[View](/bg/documents/overview/opdualag-epar-medicine-overview_bg.pdf)

español (ES) (106.46 KB - PDF)

**First published:**

20/09/2022

[View](/es/documents/overview/opdualag-epar-medicine-overview_es.pdf)

čeština (CS) (127.59 KB - PDF)

**First published:**

20/09/2022

[View](/cs/documents/overview/opdualag-epar-medicine-overview_cs.pdf)

dansk (DA) (104.94 KB - PDF)

**First published:**

20/09/2022

[View](/da/documents/overview/opdualag-epar-medicine-overview_da.pdf)

Deutsch (DE) (108.77 KB - PDF)

**First published:**

20/09/2022

[View](/de/documents/overview/opdualag-epar-medicine-overview_de.pdf)

eesti keel (ET) (93.15 KB - PDF)

**First published:**

20/09/2022

[View](/et/documents/overview/opdualag-epar-medicine-overview_et.pdf)

ελληνικά (EL) (132.16 KB - PDF)

**First published:**

20/09/2022

[View](/el/documents/overview/opdualag-epar-medicine-overview_el.pdf)

français (FR) (107.39 KB - PDF)

**First published:**

20/09/2022

[View](/fr/documents/overview/opdualag-epar-medicine-overview_fr.pdf)

hrvatski (HR) (127.44 KB - PDF)

**First published:**

20/09/2022

[View](/hr/documents/overview/opdualag-epar-medicine-overview_hr.pdf)

italiano (IT) (105.29 KB - PDF)

**First published:**

20/09/2022

[View](/it/documents/overview/opdualag-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (136.64 KB - PDF)

**First published:**

20/09/2022

[View](/lv/documents/overview/opdualag-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (128.43 KB - PDF)

**First published:**

20/09/2022

[View](/lt/documents/overview/opdualag-epar-medicine-overview_lt.pdf)

magyar (HU) (126.71 KB - PDF)

**First published:**

20/09/2022

[View](/hu/documents/overview/opdualag-epar-medicine-overview_hu.pdf)

Malti (MT) (130.68 KB - PDF)

**First published:**

20/09/2022

[View](/mt/documents/overview/opdualag-epar-medicine-overview_mt.pdf)

Nederlands (NL) (106.1 KB - PDF)

**First published:**

20/09/2022

[View](/nl/documents/overview/opdualag-epar-medicine-overview_nl.pdf)

polski (PL) (130 KB - PDF)

**First published:**

20/09/2022

[View](/pl/documents/overview/opdualag-epar-medicine-overview_pl.pdf)

português (PT) (106.97 KB - PDF)

**First published:**

20/09/2022

[View](/pt/documents/overview/opdualag-epar-medicine-overview_pt.pdf)

română (RO) (126.23 KB - PDF)

**First published:**

20/09/2022

[View](/ro/documents/overview/opdualag-epar-medicine-overview_ro.pdf)

slovenčina (SK) (127.82 KB - PDF)

**First published:**

20/09/2022

[View](/sk/documents/overview/opdualag-epar-medicine-overview_sk.pdf)

slovenščina (SL) (154.43 KB - PDF)

**First published:**

20/09/2022

[View](/sl/documents/overview/opdualag-epar-medicine-overview_sl.pdf)

Suomi (FI) (103.72 KB - PDF)

**First published:**

20/09/2022

[View](/fi/documents/overview/opdualag-epar-medicine-overview_fi.pdf)

svenska (SV) (103.87 KB - PDF)

**First published:**

20/09/2022

[View](/sv/documents/overview/opdualag-epar-medicine-overview_sv.pdf)

Opdualag : EPAR - Risk management plan

English (EN) (5.12 MB - PDF)

**First published:** 20/09/2022

**Last updated:** 24/11/2025

[View](/en/documents/rmp/opdualag-epar-risk-management-plan_en.pdf)

## Product information

Opdualag : EPAR - Product Information

English (EN) (492.34 KB - PDF)

**First published:** 20/09/2022

**Last updated:** 24/07/2025

[View](/en/documents/product-information/opdualag-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-907)

български (BG) (615.4 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/bg/documents/product-information/opdualag-epar-product-information_bg.pdf)

español (ES) (494.56 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/es/documents/product-information/opdualag-epar-product-information_es.pdf)

čeština (CS) (583.63 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/cs/documents/product-information/opdualag-epar-product-information_cs.pdf)

dansk (DA) (479.95 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/da/documents/product-information/opdualag-epar-product-information_da.pdf)

Deutsch (DE) (518.99 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/de/documents/product-information/opdualag-epar-product-information_de.pdf)

eesti keel (ET) (487.8 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/et/documents/product-information/opdualag-epar-product-information_et.pdf)

ελληνικά (EL) (625.15 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/el/documents/product-information/opdualag-epar-product-information_el.pdf)

français (FR) (508.29 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/fr/documents/product-information/opdualag-epar-product-information_fr.pdf)

hrvatski (HR) (650.91 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/hr/documents/product-information/opdualag-epar-product-information_hr.pdf)

íslenska (IS) (606.3 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/is/documents/product-information/opdualag-epar-product-information_is.pdf)

italiano (IT) (614.67 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/it/documents/product-information/opdualag-epar-product-information_it.pdf)

latviešu valoda (LV) (579.61 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/lv/documents/product-information/opdualag-epar-product-information_lv.pdf)

lietuvių kalba (LT) (579.86 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/lt/documents/product-information/opdualag-epar-product-information_lt.pdf)

magyar (HU) (598.19 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/hu/documents/product-information/opdualag-epar-product-information_hu.pdf)

Malti (MT) (601.54 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/mt/documents/product-information/opdualag-epar-product-information_mt.pdf)

Nederlands (NL) (494.3 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/nl/documents/product-information/opdualag-epar-product-information_nl.pdf)

norsk (NO) (370.22 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/no/documents/product-information/opdualag-epar-product-information_no.pdf)

polski (PL) (613.76 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/pl/documents/product-information/opdualag-epar-product-information_pl.pdf)

português (PT) (605.4 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/pt/documents/product-information/opdualag-epar-product-information_pt.pdf)

română (RO) (584.23 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/ro/documents/product-information/opdualag-epar-product-information_ro.pdf)

slovenčina (SK) (682.88 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/sk/documents/product-information/opdualag-epar-product-information_sk.pdf)

slovenščina (SL) (583 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/sl/documents/product-information/opdualag-epar-product-information_sl.pdf)

Suomi (FI) (480.38 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/fi/documents/product-information/opdualag-epar-product-information_fi.pdf)

svenska (SV) (588.48 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/07/2025

[View](/sv/documents/product-information/opdualag-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00011018/202409 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Opdualag : EPAR - All authorised presentations

English (EN) (44.95 KB - PDF)

**First published:** 20/09/2022

[View](/en/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_en.pdf)

[Other languages (25)](#file-language-dropdown-359)

български (BG) (55.12 KB - PDF)

**First published:**

20/09/2022

[View](/bg/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_bg.pdf)

español (ES) (71.31 KB - PDF)

**First published:**

20/09/2022

[View](/es/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_es.pdf)

čeština (CS) (96.19 KB - PDF)

**First published:**

20/09/2022

[View](/cs/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.25 KB - PDF)

**First published:**

20/09/2022

[View](/da/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (46.65 KB - PDF)

**First published:**

20/09/2022

[View](/de/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.08 KB - PDF)

**First published:**

20/09/2022

[View](/et/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.68 KB - PDF)

**First published:**

20/09/2022

[View](/el/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_el.pdf)

français (FR) (44.97 KB - PDF)

**First published:**

20/09/2022

[View](/fr/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.89 KB - PDF)

**First published:**

20/09/2022

[View](/hr/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (46.62 KB - PDF)

**First published:**

20/09/2022

[View](/is/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_is.pdf)

Gaeilge (GA) (45.4 KB - PDF)

**First published:**

20/09/2022

[View](/ga/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_ga.pdf)

italiano (IT) (44.95 KB - PDF)

**First published:**

20/09/2022

[View](/it/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.94 KB - PDF)

**First published:**

20/09/2022

[View](/lv/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.83 KB - PDF)

**First published:**

20/09/2022

[View](/lt/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (78.09 KB - PDF)

**First published:**

20/09/2022

[View](/hu/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.66 KB - PDF)

**First published:**

20/09/2022

[View](/mt/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.21 KB - PDF)

**First published:**

20/09/2022

[View](/nl/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (75.16 KB - PDF)

**First published:**

20/09/2022

[View](/no/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_no.pdf)

polski (PL) (93.33 KB - PDF)

**First published:**

20/09/2022

[View](/pl/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.71 KB - PDF)

**First published:**

20/09/2022

[View](/pt/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_pt.pdf)

română (RO) (63.01 KB - PDF)

**First published:**

20/09/2022

[View](/ro/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.79 KB - PDF)

**First published:**

20/09/2022

[View](/sk/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (82.56 KB - PDF)

**First published:**

20/09/2022

[View](/sl/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (68.79 KB - PDF)

**First published:**

20/09/2022

[View](/fi/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.62 KB - PDF)

**First published:**

20/09/2022

[View](/sv/documents/all-authorised-presentations/opdualag-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Opdualag Active substance

- nivolumab
- relatlimab

International non-proprietary name (INN) or common name

- relatlimab
- nivolumab

Therapeutic area (MeSH) Melanoma Anatomical therapeutic chemical (ATC) code L01FY02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression &lt; 1%.

## Authorisation details

EMA product number EMEA/H/C/005481

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 21/07/2022 Marketing authorisation issued 15/09/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Opdualag : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.13 KB - PDF)

**First published:** 11/07/2025

**Last updated:** 24/11/2025

[View](/en/documents/procedural-steps-after/opdualag-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Opdualag : EPAR - Procedural steps taken and scientific information after authorisation (archive)

Adopted

English (EN) (137.13 KB - PDF)

**First published:** 21/02/2024

**Last updated:** 11/07/2025

[View](/en/documents/procedural-steps-after/opdualag-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Odualag : EPAR - Scientific conclusions - Annex IV

English (EN) (128.57 KB - PDF)

**First published:** 24/07/2025

[View](/en/documents/scientific-conclusion/odualag-epar-scientific-conclusions-annex-iv_en.pdf)

Opdualag-H-C-PSUSA-00011018-202403: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/531182/2024

English (EN) (130.92 KB - PDF)

**First published:** 06/01/2025

[View](/en/documents/scientific-conclusion/opdualag-h-c-psusa-00011018-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Opdualag : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/720884/2022

English (EN) (5.32 MB - PDF)

**First published:** 20/09/2022

[View](/en/documents/assessment-report/opdualag-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Opdualag

Adopted

Reference Number: EMA/CHMP/617724/2022

English (EN) (163.32 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-opdualag_en.pdf)

#### News on Opdualag

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Opdualag : EPAR - Product information - tracked changes

English (EN) (302.26 KB - DOCX)

**First published:** 24/07/2025

[View](/en/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-519)

български (BG) (295.4 KB - DOCX)

**First published:**

24/07/2025

[View](/bg/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_bg.docx)

español (ES) (294.12 KB - DOCX)

**First published:**

24/07/2025

[View](/es/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_es.docx)

čeština (CS) (297.42 KB - DOCX)

**First published:**

24/07/2025

[View](/cs/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (300.31 KB - DOCX)

**First published:**

24/07/2025

[View](/da/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (290.31 KB - DOCX)

**First published:**

24/07/2025

[View](/de/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (291.82 KB - DOCX)

**First published:**

24/07/2025

[View](/et/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (306.99 KB - DOCX)

**First published:**

24/07/2025

[View](/el/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_el.docx)

français (FR) (298.16 KB - DOCX)

**First published:**

24/07/2025

[View](/fr/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (295.94 KB - DOCX)

**First published:**

24/07/2025

[View](/hr/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (300.26 KB - DOCX)

**First published:**

24/07/2025

[View](/is/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_is.docx)

italiano (IT) (300.03 KB - DOCX)

**First published:**

24/07/2025

[View](/it/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (296.14 KB - DOCX)

**First published:**

24/07/2025

[View](/lv/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (294.4 KB - DOCX)

**First published:**

24/07/2025

[View](/lt/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (314.93 KB - DOCX)

**First published:**

24/07/2025

[View](/hu/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (295.6 KB - DOCX)

**First published:**

24/07/2025

[View](/mt/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (291.7 KB - DOCX)

**First published:**

24/07/2025

[View](/nl/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (293.28 KB - DOCX)

**First published:**

24/07/2025

[View](/no/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_no.docx)

polski (PL) (476.92 KB - DOCX)

**First published:**

24/07/2025

[View](/pl/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_pl.docx)

português (PT) (298.86 KB - DOCX)

**First published:**

24/07/2025

[View](/pt/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_pt.docx)

română (RO) (294.35 KB - DOCX)

**First published:**

24/07/2025

[View](/ro/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (299.28 KB - DOCX)

**First published:**

24/07/2025

[View](/sk/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (292.21 KB - DOCX)

**First published:**

24/07/2025

[View](/sl/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (290.05 KB - DOCX)

**First published:**

24/07/2025

[View](/fi/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (297.46 KB - DOCX)

**First published:**

24/07/2025

[View](/sv/documents/product-information-tracked-changes/opdualag-epar-product-information-tracked-changes_sv.docx)

#### More information on Opdualag

- [EMEA-002727-PIP02-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002727-pip02-23)
- [EMEA-002727-PIP03-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002727-pip03-23)
- [Long-term follow-up of pediatric patients exposed to nivolumab + relatlimab fixed-dose combination (FDC) enrolled in the Dutch Melanoma Treatment Registry (DMTR) (CA224-122) - post-authorisation study](https://catalogues.ema.europa.eu/study/107907)

**This page was last updated on** 24/11/2025

## Share this page

[Back to top](#main-content)